Skip to main content
SpringerLink
Log in

DPP-4 inhibitors tolerable option for T2DM patients

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wu S, et al. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics : [43 pages], 18 Aug 2017. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2017.07.036

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DPP-4 inhibitors tolerable option for T2DM patients. Reactions Weekly 1667, 5 (2017). https://doi.org/10.1007/s40278-017-35137-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-35137-5

Search

Navigation